To include your compound in the COVID-19 Resource Center, submit it here.

Alnylam, Sanofi restructure RNAi therapeutics deal

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) gained global development and commercialization rights to transthyretin (TTR)-mediated amyloidosis candidates patisiran (ALN-TTR02) and ALN-TTRsc02 after it and Sanofi (Euronext:SAN; NYSE:SNY) amended their 2012 deal. The pharma and its Sanofi Genzyme

Read the full 358 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE